Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anecortave Acetate in exudative AMD
NCT00051129Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jan 2007
- Primary completion
- May 2008
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of anecortave in age-related macular degeneration (AMD), sponsored by Alcon Inc. Primary endpoint: Mean change from baseline in logMAR visual acuity score at 12 months. Started Jan 2007; status: completed.
02
Drugs
anecortave
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00051129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051129.